# General description

<table>
<thead>
<tr>
<th>INN</th>
<th>Methotrexate</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>L01BA01 L04AX03</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
</tbody>
</table>

**EML status history**

- First added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 1997 (TRS 882) for Rheumatoid arthritis, serology unspecified
- Added in 2011 (TRS 965) for Juvenile idiopathic arthritis
- Added in 2015 (TRS 994) for Malignant neoplasms of breast
- Added in 2015 (TRS 994) for Malignant trophoblastic neoplasms of placenta
- Added in 2015 (TRS 994) for Osteosarcoma of bone and articular cartilage of unspecified sites
- Added in 2015 (TRS 994) for Lymphoid leukaemia, not elsewhere classified
- Added in 2015 (TRS 994) for Acute myeloid leukaemia with recurrent genetic abnormalities
- Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2021 (TRS 1035) for Burkitt lymphoma including Burkitt leukaemia
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative
- Added in 2023 (TRS 1049) for Langerhans cell histiocytosis
- Added in 2023 (TRS 1049) for Psoriasis of unspecified type
- Application rejected in 2023 (TRS 1049) for Crohn disease site
- Application rejected in 2023 (TRS 1049) for Psoriatic arthritis

---

## Recommendations

[DrugBank](https://www.drugbank.ca/drugs/DB00426)  
Methotrexate

[Wikipedia](https://en.wikipedia.org/wiki/Methotrexate)  
Methotrexate
### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

**Indications**

- Malignant neoplasms of breast
- Malignant trophoblastic neoplasms of placenta
- Osteosarcoma of bone and articular cartilage of unspecified sites
- Lymphoid leukaemia, not elsewhere classified
- Acute myeloid leukaemia with recurrent genetic abnormalities
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Burkitt lymphoma including Burkitt leukaemia
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Langerhans cell histiocytosis

### Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 2.5 mg (as sodium salt)

**Indications**

- Rheumatoid arthritis, serology unspecified

### Medicines for juvenile joint diseases

Oral > Solid > tablet: 2.5 mg (as sodium salt)

**Indications**

- Juvenile idiopathic arthritis
**Dermatological medicines > Medicines affecting skin differentiation and proliferation**

Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

**Indications**

- Psoriasis of unspecified type

**Immunomodulators for non-malignant disease**

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

**Indications**

- Crohn disease site
- Psoriatic arthritis